Delcath Systems, Inc., a company specializing in interventional oncology for liver cancers, has announced the acceptance of an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. The presentation will cover results from the CHOPIN Phase 2 trial, which is an investigator-initiated study evaluating the safety, tolerability, and efficacy of combining systemic ipilimumab and nivolumab with Delcath's CHEMOSAT® Hepatic Delivery System. The study focuses on patients with metastatic uveal melanoma. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center, will present the findings on October 18, 2025. The presentation's abstract is numbered LBA59 and will be featured in the session titled "Melanoma and other skin tumours." Further details will become available on Delcath's website after the ESMO embargo is lifted on the presentation date.